BioSig Technologies' Common Stock To Resume Trading On The Nasdaq Exchange, Wednesday, October 23, 2024 After Its Appeal Was Granted An Extension Until March 7, 2025
BioSig Technologies' Common Stock To Resume Trading On The Nasdaq Exchange, Wednesday, October 23, 2024 After Its Appeal Was Granted An Extension Until March 7, 2025
BioSig Technologies, Inc. (OTCQB:BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company's common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities ("MVLS") requirement previously became non-compliant.
BioSig Technologies, Inc. (OTCQB:BSGM)（"BioSig"或"公司"），一家医疗科技公司，为心脏内信号可视化提供前所未有的准确性和精度，今天宣布成功上诉纳斯达克委员会（NASDAQ Panel），因此公司的普通股将于2024年10月23日星期三开市时恢复在纳斯达克资本市场交易所交易。公司获得了延期至2025年3月7日的授权，这是自市值证券上市要求不符合的时点起的360天容忍期。
